Deskside with Dr. Dan
FDA grants accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
As of December 2020, the Food and Drug Administration (FDA) has granted accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Gryt Health Chief Medical Officer, Dr. Dan breaks down the announcement.
Gryt Health
June 21, 2022
